BRIDGING PLENARY SESSION
(JOINT SESSION BETWEEN STRATEGIC RESOURCE
MANAGEMENT & PORTFOLIO MANAGEMENT FORUMS)
1:55 Chairperson’s Remarks
Robin G. Foldesy, Ph.D., Vice President, Portfolio Management, Wyeth Research
2:00 The Intersection of Molecules and Stocks
Michael Shulman, Editor/Analyst, ChangeWave
Wall Street is a mystery to many – including many who work there! In this session, Michael Shulman, a research analyst, TV commentator and editor of the ChangeWave Biotech Investor Service will de-mystify Wall Street – as best as possible. Understanding Wall Street is more critical to the everyday activities of both big and small life sciences companies than many think. In an industry where non-revenue, non-profit events and milestones can have a dramatic impact on share prices, employees, managers, even CEOs are often at a loss to understand why their stock may move up or down – and are therefore ill-equipped to deal with and manage this volatility. A good deal of this movement in stock prices is based on Wall Street’s perception of a company’s technology, product pipeline and prospects in the market place – ten weeks, ten months or ten years in the future. And, despite the long term horizon the strategic planning process needs to include explicit consideration of the intersection of corporate milestones and the value of a stock. This session covers what criteria investors are looking for and how to avoid surprises when building and positioning a portfolio and product pipeline to investors. Small, pre-revenue companies and big companies have far different paths and both will be discussed by Mr. Shulman. Three focal points of the presentation:
- How Wall Street Operates -- Short versus Long Term Investor Behavior
- Drivers of stock prices
- The Street view of catalysts
- Big cap versus small cap
- Investing Catalysts: -- Molecules, Trials, Partnerships and Approvals
- As a corporate event or milestone
- As a driver of a stock price
- Managing Through Stock Volatility – Case Studies
2:30 Trends in Portfolio Management: New Questions Addressed with Different Information
Jeff Hewitt, Vice President, SDG life sciences, a unit of IMS
As the challenges for many of the larger players in the industry have shifted, so have the approaches for managing value in the portfolio. This talk will provide a look at how the trends in the industry have shifted -and how portfolio management questions are being addressed. Case examples to illustrate those trends include:
- Choosing areas of therapeutic focus with an understanding of competitive advantage
- Taking a portfolio perspective to pull more value out of mature brands
- Developing portfolio strategies for investing behind emerging markets
3:00 Networking Refreshment Break
4:00 Valuing a Diverse Portfolio: The Move from Selling Medicines to Promoting Health
Marilyn Metcalf, Ph.D., Director, Quantitative and Decision Sciences, GlaxoSmithKline
In a business environment that is moving increasingly toward services and information, rather than the more traditional production and sale of goods, how will pharmaceutical firms value and shape their business? As we seek to promote healthier lifestyles, disease prevention as well as treatment, global programs that provide greater access to medicines in nontraditional markets, public-private partnerships, and new business models, we no longer have only a portfolio of material assets to consider. This presentation will explore how decision sciences can help pharma companies of the future consider
- Valuation of technologies
- Impact to different types of investors (e.g., traditional and socially responsible)
- Bundling of services, tests, and treatments
- Benefits of health promotion
4:30 Portfolio Management in the Pharmaceutical Commercialization Space
Poplin Kroese, Senior Analyst, Portfolio Management Strategy Deployment, Merck & Co.
Portfolio management is traditionally done at the company level or within drug discovery and clinical development, where decisions to progress or not progress with whole programs can be made. At Merck, we’ve extended the principles of portfolio management beyond the clinical spheres to the global development and commercialization of the products themselves. The key difference for our process being we are fed a portfolio of “what” the company wants to pursue. These company directives, in addition to factors in the commercialization space, are then used to determine “how” best to meet the company goals. The presentation will cover:
- How to optimize execution of a portfolio that is pre-determined by the company
- An approach to align a cross functional, decision making council in the Commercialization space
- The use of Design for Six Sigma and Change Execution methodology in developing this complex process.
5:00 Successful Portfolio Management within Discovery at AstraZeneca
Richard Lawson, Ph.D., Global Head of Discovery Decision Support, Discovery Strategy and Performance, AstraZeneca Pharmaceuticals, Inc.
AstraZeneca has successfully implemented a global portfolio management environment for its drug discovery projects. Success here was built on an appreciation of the unique challenges and benefits in a research setting relative to the more traditional implementations in development and corporate settings. Despite significant technical and cultural differences, AstraZeneca is now working toward an “appropriately” integrated approach to portfolio management across research and development.
- The benefits of a portfolio management environment in a research setting
- Key differences between portfolio management in research versus development
- How AstraZeneca plans to bridge the gap between research and Development in terms of both technical and cultural issues related to portfolio management
5:30 Close Day One and End of Strategic Resource Management
(Portfolio Management continues on through Wednesday, November 19th)
Overview | Day 1 | Day 2 | Go to Strategic Resource Management Conference